ELMWOOD PARK, N.J., Dec. 18, 2012 /PRNewswire/ -- Bio-Reference Laboratories, Inc. (NASDAQ: BRLI), a national clinical testing laboratory, has announced its donation of $100,000 to the Hurricane Sandy New Jersey Relief Fund. The Fund has been established to help New Jersey citizens rebuild after the devastation caused last month by the storm. "There are moments when we are confronted with events so overwhelming and destructive that the question is not whether we should help but rather how can we not help. Hurricane Sandy provided one of those moments. Those affected were our neighbors, friends, and co-workers. Experiencing the devastation that was Hurricane Sandy in our own state has hit home with the entire Bio-Reference family," stated Marc Grodman, MD, President and CEO of Bio-Reference Laboratories. "Our business may be national in scope, but we remain a New Jersey-based company and we could not stand by doing nothing while witnessing the impact to families and small business owners all around us – especially in our immediate neighborhood of Bergen County, where communities still are struggling to recover." Hurricane Sandy New Jersey Relief Fund Inc. is a private independent charitable organization that is registered with the Charities Registration and Investigation Section of the Division of Consumer Affairs under the Attorney General of the State of New Jersey. "We employ more than 3,500 people at Bio-Reference Laboratories, most of whom live in New Jersey, many who live in this immediate area. Every one of us has a family member or friend affected by the storm – while others were impacted directly," added Grodman. "We hope that, through the Hurricane Sandy New Jersey Relief Fund, we can help to rebuild our communities and help those families most in need who might otherwise fall through the cracks and not receive the kind of assistance they require to rebuild." About Bio-Reference Laboratories, Inc. BRLI is a clinical testing laboratory offering testing, information and related services to physician offices, clinics, hospitals, employers and governmental units. We believe that we are the fourth largest full-service laboratory in the United States and the largest independent regional laboratory in the Northeastern market. BRLI offers a comprehensive list of laboratory testing services utilized by healthcare providers in the detection, diagnosis, evaluation, monitoring and treatment of diseases. BRLI primarily focuses on esoteric testing, molecular diagnostics, anatomical pathology, women's health and correctional health care. Statements included in this release that are not historical in nature are intended to be, and are hereby identified as, "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by words such as "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates," "will" or words of similar meaning and include, but are not limited to, statements about the expected future business and financial performance of Bio-Reference Laboratories, Inc. and its subsidiaries. Such statements involve known and unknown risks and uncertainties that may cause the Company's actual results in future periods to be materially different from any future performance suggested herein. Risks and uncertainties that may affect the future results of the Company include, but are not limited to, adverse results from failure to comply with applicable laws and regulations governing our business or government investigations, lawsuits or private actions, the competitive environment, changes in government regulations, changing relationships with customers, payers, suppliers and strategic partners and other risks and uncertainties detailed from time to time in our filings with the Securities and Exchange Commission. We undertake no obligation to publicly update or review any forward-looking information, whether as a result of new information, future developments or otherwise. SOURCE Bio-Reference Laboratories, Inc.